Clinical Trials Logo

Smoking clinical trials

View clinical trials related to Smoking.

Filter by:

NCT ID: NCT01348646 Completed - Smoking Clinical Trials

Adult Follow-up of Preventive Study With Brief Smoking Intervention for Adolescents

TuNAMI
Start date: May 2008
Phase: N/A
Study type: Interventional

The purpose of this study was to see whether a brief intervention given in adolescence has an effect on smoking in adulthood. The investigators also wanted to clarify the significance of some known psychosocial risk factors of smoking in adulthood.

NCT ID: NCT01347112 Completed - Smoking Clinical Trials

Varenicline Treatment for Active Alcoholic Smokers

Start date: June 2011
Phase: Phase 2/Phase 3
Study type: Interventional

Alcohol dependence is a significant and prevalent public health problem affecting approximately 4% of the U.S. adult population. Individuals with alcohol dependence actively seek treatment annually, and long-term alcohol abstinence varies from 40-60%. Because of the high smoking prevalence and trends toward heavier smoking, alcoholic smokers are at high risk for both morbidity and mortality related to alcohol consumption and tobacco dependence. Although several studies have evaluated pharmacotherapy for tobacco dependence in recovering alcoholic smokers, few have evaluated pharmacotherapy for tobacco dependence among currently drinking alcoholic smokers. Varenicline is the most effective medication currently available for treating tobacco dependence. While some randomized trials have included recovering alcoholics, active alcoholism has been an exclusion criteria for these trials. Thus, this proposal would be the first such clinical trial in currently drinking alcoholic smokers. In addition to helping smokers to stop smoking, varenicline has also been shown to reduce alcohol consumption in rats. The goal of this proposal is to explore the potential efficacy of varenicline for treating tobacco dependence and reducing drinking among alcohol dependent smokers. The investigators hypothesize that 12 weeks of treatment with varenicline, a partial nicotinic acetylcholine receptor agonist will be more effective than placebo in treating tobacco dependence and reducing nicotine withdrawal symptoms in currently drinking alcoholic smokers. The investigators will also explore whether varenicline has an effect on drinking behavior among currently drinking alcoholics. The investigators propose the following specific aims to test these hypotheses in 70 currently drinking alcoholic smokers recruited at the Mayo Clinic in Rochester, Minnesota.

NCT ID: NCT01346956 Completed - Smoking Clinical Trials

Acute Cardiovascular Effects of Cigarette Smoking

Start date: July 2002
Phase: N/A
Study type: Observational

Twenty healthy smokers will be subjected to measurement of Pulse, Blood Pressure, electrocardiogram (ECG) and Echo at baseline and after smoking a cigarette. The measurements will be compare for any cardiovascular effects of a cigarette smoking on these parameters.

NCT ID: NCT01342523 Completed - Smoking Cessation Clinical Trials

Evaluation of National Cancer Institute (NCI) Smoking Intervention Resources

NCI
Start date: October 2011
Phase: Phase 4
Study type: Interventional

This is an evaluative study of three National Cancer Institute (NCI) smoking cessation resources: specifically, the smokefree.gov and women smokefree.gov websites, and the CIS counseling phone calls. The following are the identified critical questions: (1). How effective is each of the tobacco interventions (websites [smokefree.gov & women smokefree.gov], NCI's Cessation Quitline counseling services operated by the Cancer Information Service (CIS) (2). How do they compare with alternative intervention strategies? (3). Which types of interventions appear to work best together (due to additive or interactive effects)? (4). How do these interventions work? (5). How much are these interventions used, and what are their relative use rates? (6). Are there important differences in effectiveness or use rates as a function of gender, SES, or other important person factors? We believe that the research study will address all of these questions, as well as some less central ones.

NCT ID: NCT01337830 Completed - Smoking Clinical Trials

Pilot Study to Evaluate the Safety and Efficacy of Ariva® Silver Wintergreen in Reducing Cigarette Craving in Smokers

Start date: October 2010
Phase: Phase 1
Study type: Interventional

Study to determine the safety and effectiveness of Ariva® Silver Wintergreen lozenge on reducing craving for a cigarette in daily smokers.

NCT ID: NCT01337817 Completed - Smoking Clinical Trials

A Pilot Study to Evaluate the Efficacy and Safety of Ariva® Silver Wintergreen in Healthy Smokers

Start date: September 2009
Phase: Phase 1
Study type: Interventional

Study to determine the safety and effectiveness of silver salt in Ariva® Silver Wintergreen Lozenge on discouraging smoking, by its imparting an unfavorable taste to the smoker when tobacco is smoked.

NCT ID: NCT01336816 Completed - Smoking Clinical Trials

A Pilot Study to Evaluate the Efficacy of Ariva® Silver Wintergreen, a Smoking Aversive Lozenge

Start date: July 2009
Phase: Phase 1
Study type: Interventional

This is a study to determine the safety and effectiveness of silver salt in Ariva® Silver Wintergreen Lozenge on discouraging smoking, by its imparting an unfavorable taste to the smoker when tobacco is smoked.

NCT ID: NCT01328431 Completed - Smoking Cessation Clinical Trials

Treating Low-Income Smokers in the Hospital Emergency Department

Start date: October 2010
Phase: N/A
Study type: Interventional

This study will test the effectiveness of an Emergency Department (ED) initiated tobacco intervention which includes counseling and medication. Our proposed intervention combines a Brief Negotiated Interview (BNI) with initiation of nicotine patch and gum in the ED, as well as a faxed referral to the state's Smokers' Quitline. A 6 week supply of nicotine patches and nicotine gum are provided to subjects in the intervention arm. Subjects randomized to the control arm will receive a brochure from the state's Smokers' Quitline only. The primary hypothesis is that the intervention will be superior to the control condition in reducing self-reported and biochemically verified 7-day tobacco abstinence at 3 months.

NCT ID: NCT01326234 Withdrawn - Smoking Clinical Trials

Computer-Based Program to Facilitate Readiness and Motivation for Smoking Cessation

Start date: June 2010
Phase: N/A
Study type: Interventional

The current study seeks to use a computer-based program to target parents of children who smoke. Parents will be randomly assigned to either receive personalized feedback about their smoking behaviors or not. One month after gathering their baseline information, all participants will be asked to complete follow-up questionnaires online assessing their smoking behaviors.

NCT ID: NCT01325727 Completed - Smoking Clinical Trials

Brief Computerized Feedback for Smokers in Recovery

Start date: March 2011
Phase: N/A
Study type: Interventional

The purpose of this research study is to find out more about smokers in recovery from addiction to alcohol/other drugs, and to evaluate a brief computerized smoking behavior feedback session. The hypothesis is that a brief computerized smoking behavior feedback session will motivate more smokers to quit smoking than a control condition.